Results 41 to 50 of about 25,878 (248)
Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings. [PDF]
Neural Regen Res, 2023 Type-B monoamine oxidase inhibitors, encompassing selegiline, rasagiline, and safinamide, are available to treat Parkinson's disease. These drugs ameliorate motor symptoms and improve motor fluctuation in the advanced stages of the disease. There is also
Alborghetti M +5 more
europepmc +2 more sources
Coumarin analogue 3-methyl-7H-furo[3,2-g] chromen-7-one as a possible antiparkinsonian agent
Biomédica: revista del Instituto Nacional de Salud, 2019 Introduction: Parkinson’s disease is the second most common neurodegenerative disease. Monoamine oxidase B inhibitors are used in the treatment of this disease concomitantly with levodopa or as monotherapy.
María del Pilar Olaya +4 more
doaj +1 more source
PYRAZOLINES WITH ANTICONVULSANT AND MAO INHIBITORY ACTIVITIES [PDF]
Al-Azhar Journal of Pharmaceutical Sciences, 2014 2-Pyrazolines (4,5-dihydro-1H-pyrazole) are an important class of five-membered heterocyclic compounds and were found to be vital building block in medicinal chemistry and led to the discovery of a number of bioactive derivatives.
Mohamed Aboul-Enein
doaj +1 more source
Structure-Activity Relationship Analysis of 3-Phenylcoumarin-Based Monoamine Oxidase B Inhibitors
Frontiers in Chemistry, 2018 Monoamine oxidase B (MAO-B) catalyzes deamination of monoamines such as neurotransmitters dopamine and norepinephrine. Accordingly, small-molecule MAO-B inhibitors potentially alleviate the symptoms of dopamine-linked neuropathologies such as depression ...
Sanna Rauhamäki +20 more
doaj +1 more source
Journal of Lipid Research, 1963 The norepinephrine content of adipose tissue is shown to be very different in various animal species and different sites of origin, ranging from 0.03-1.4 μg/g. Adipose tissue also contains considerable amounts of serotonin (0.01-1.04 μg/g) and histamine (
K. Stock, E.O. Westermann
doaj +1 more source
Advanced Science, EarlyView.ABSTRACT Accumulating evidence suggests that the intestinal microbiota participates in the progression of metabolic dysfunction‐associated steatotic liver disease (MASLD) through microbiota‐host interaction. However, the beneficial role of commensal mycobiota in MASLD progression remains poorly understood.
Shuping Qiao +11 more
wiley +1 more source
Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson’s Disease: Past, Present, and Future
Journal of Parkinson’s Disease, 2022 Monoamine oxidase-B (MAO-B) inhibitors are commonly used for the symptomatic treatment of Parkinson’s disease (PD). MAO-B inhibitor monotherapy has been shown to be effective and safe for the treatment of early-stage PD, while MAO-B inhibitors as ...
Yu-Yan Tan, Peter Jenner, Sheng-Di Chen
doaj +1 more source
Stress reduces in vivo inhibition of monoamine oxidase by phenelzine in rat brain
, 1989 The level of inhibition of rat whole brain monoamine oxidase activity produced by the irreversible monoamine oxidase inhibitor phenelzine has been studied with or without concurrent cold restraint stress.
Glover, V. +3 more
core +1 more source
Multimodal Imaging Reveals Rapid Catecholamine Uptake and Release by Neutrophils
Advanced Science, EarlyView.We show that immune cells (neutrophils) synthesize, uptake, and store catecholamine neurotransmitters such as dopamine or adrenaline. They also release them in response to specific stimuli (serotonin), which we directly visualize using fluorescent nanosensors. We further demonstrate that catecholamines affect neutrophil functions (NETosis) and platelet
Jennifer Mohr +19 more
wiley +1 more source
Interaction between phenylpropanolamine and monoamine oxidase inhibitors
, 1969 The role of monoamine oxidase in the potentiation of the pressor effect of phenylpropanolamine (norephedrine) by monoamine oxidase inhibitors has been investigated.
A D’Mello
core +1 more source